JDRF T1D Fund

The JDRF T1D Fund is a venture philanthropy fund dedicated to accelerating life-changing solutions for type 1 diabetes (T1D) by catalyzing investments in T1D-focused companies. Established in 2016 as an independently run subsidiary of Breakthrough T1D, the Fund addresses the lack of private investment in T1D, aiming to bridge the gap between scientific advancements and the delivery of solutions to those living with or at risk of developing T1D. By partnering with private capital, including venture capital, corporations, and foundations, the Fund seeks to attract the necessary investments to advance drugs, devices, diagnostics, and vaccines into the hands of those living with T1D. The Fund reinvests any realized gains into new investments to further its mission.

Operating as a wholly owned, independently governed, not-for-profit subsidiary of Breakthrough T1D, the Fund leverages the expansive network of the foundation across all areas of treatment, from early-stage research to government advocacy. This relationship enables the Fund to invest in the most promising opportunities while continuing to provide support to its portfolio across the development life cycle. The Fund's investment strategy focuses on cure-oriented therapies, investing in areas strategically aligned with Breakthrough T1D and the Helmsley Charitable Trust, the leading global organizations funding T1D research and working to change the lives of those affected by T1D. The Fund is managed by a dedicated team of investment professionals, and all realized gains are reinvested into new investments aligned with its mission to cure T1D.

Since its launch, the JDRF T1D Fund has invested in more than forty private and public companies, emphasizing cure-oriented therapies. The Fund operates as a powerful platform for collaboration, using catalytic capital and expertise to de-risk investments and create a flywheel effect that attracts other investors to the T1D space. By partnering with innovators, the Fund accelerates the development of disease-modifying therapies and cures, with all returns reinvested to create a continuous cycle of progress that fuels foundational research and accelerates program development. The Fund's approach has influenced philanthropies, pharmaceutical companies, and other venture capital firms to invest billions of dollars alongside it, generating cure-oriented therapies for T1D. The Fund's commitment to its mission is underscored by its appointment of experienced leaders, such as Sylvia Tobé, PhD, as Managing Director, to advance and broaden its investment activities and capabilities. Dr. Tobé brings significant expertise in the autoimmune disease arena, further strengthening the Fund's leadership team and its dedication to advancing its mission to expedite life-altering solutions and serve as a catalyst for significant investments aimed at curing, preventing, and treating T1D.

The JDRF T1D Fund's unique position in the T1D ecosystem allows it to transform the therapeutic landscape of T1D through its investment approach. By operating as a mission-oriented scaled venture fund with over $200 million in assets, the Fund's expertise and leadership influence philanthropies, pharmaceutical companies, and other venture capital firms to invest billions of dollars alongside it, generating cure-oriented therapies for T1D. The Fund's commitment to its mission is further demonstrated by its reinvestment of any realized gains into new investments, creating a continuous cycle of progress that fuels foundational research and accelerates program development. Through its strategic investments and partnerships, the JDRF T1D Fund plays a critical role in advancing the development of therapies and cures for type 1 diabetes, aiming to improve the lives of those affected by this chronic condition.